News | March 30, 2022
Sun Pharma gets exclusive patent licence for Vortioxetine
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
It has a total of 50 ANDA approvals from USFDA
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
Subscribe To Our Newsletter & Stay Updated
